Navigation Links
New Study Demonstrates Ramelteon Does Not Exacerbate Respiratory Depressant Effects in Patients With Moderate-to-Severe COPD
Date:12/3/2007

sleep medication that has shown no evidence of abuse or dependence in clinical studies,* and has not been designated as a controlled substance. With the exception of ROZEREM, all other prescription medications indicated for insomnia are classified as Schedule IV controlled substances by the U.S. Drug Enforcement Administration. ROZEREM has a unique therapeutic mechanism of action that targets MT1 and MT2 receptors. The activity at MT1 and MT2 receptors in the suprachiasmatic nucleus (SCN) is thought to promote sleep.

*ROZEREM is not a controlled substance. A clinical abuse liability study showed no differences indicative of abuse potential between ROZEREM and placebo at doses up to 20 times the recommended dose (N=14). Three 35-day insomnia studies showed no evidence of rebound insomnia or withdrawal symptoms with ROZEREM compared to placebo (N=2082).

Important Safety Information

ROZEREM(TM) should not be used in patients with hypersensitivity to any components of the formulation, severe hepatic impairment, or in combination with fluvoxamine. Failure of insomnia to remit after a reasonable period of time should be medically evaluated, as this may be the result of an unrecognized underlying medical disorder. Hypnotics should be administered with caution to patients exhibiting signs and symptoms of depression.

ROZEREM has not been studied in patients with severe sleep apnea or in children or adolescents. The effects in these populations are unknown. Avoid taking ROZEREM with alcohol. Studies for severe COPD have not yet been evaluated by the FDA. ROZEREM has been associated with decreased testosterone levels and increased prolactin levels. Health professionals should be mindful of any unexplained symptoms which could include cessation of menses or galactorrhea in females, decreased libido or problems with fertility that are possibly associated with such changes in these hormone levels. ROZEREM should not be taken with or immediately after a
'/>"/>

SOURCE Takeda Pharmaceuticals North America, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. New study shows promise in reducing surgical risks associated with surgical bleeding
3. Study, meta-analysis examine factors associated with death from heatstroke
4. Study suggests loss of 2 types of neurons -- not just 1 -- triggers Parkinsons symptoms
5. Study says COPD testing is not measuring up
6. Preclinical study suggests organ-transplant drug may aid in lupus fight
7. Ability to cope with stress can increase good cholesterol in older white men, study finds
8. High alcohol consumption increases stroke risk, Tulane study says
9. Mailman School of Public Health study examines link between racial discrimination and substance use
10. Pitt study finds inequality in tobacco advertising
11. Stanford study highlights cost-effective method of lowering heart disease risks
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... new lung is grown for a patient in need, using ... injection of replacement cells will enable a patient to self-heal ... ALERT: For audio and video of Dr. Keller and Jorge ... Mayo Clinic News Network . , Regenerative ... gift from Jorge and Leslie Bacardi of the Bahamas will ...
(Date:7/29/2014)... Dallas, Texas (PRWEB) July 29, 2014 ... the Global Biosimilars Market report is an essential ... biosimilars industry. Using detailed company data, financial analysis, ... in-depth analysis of the current and future growth ... the various regulatory frameworks under which biosimilars are ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 The Affordable ... reimbursement model of all hospitals. Studies show that over ... One simple, easy, low cost tool that great hospitals ... by 20 to 25%. , Their secret? Debriefing - ... anther at the end of an operational event. Debriefing ...
(Date:7/29/2014)... day lead to a more streamlined process for obtaining stem ... of replacement tissue for failing body parts, according to UC ... edition of Cell . , The work builds on ... embryonic state in which they again have the potential to ... this process may soon increase thanks to the scientists, identification ...
(Date:7/29/2014)... Little Rock, AR (PRWEB) July 29, 2014 ... S.Res.518 , a resolution declaring the week of October ... the value of case management in improving healthcare outcomes ... Pryor (D-AR) and Senator John Boozman (R-AR), with support ... American Case Management Association to honor case management professionals ...
Breaking Medicine News(10 mins):Health News:Bacardis make gift to significantly advance Mayo Clinic's regenerative medicine research 2Health News:Bacardis make gift to significantly advance Mayo Clinic's regenerative medicine research 3Health News:Bacardis make gift to significantly advance Mayo Clinic's regenerative medicine research 4Health News:World Biosimilars Market Value Exceed $262 Billion by 2019 Says a New Report Available at MarketOptimizer.org 2Health News:World Biosimilars Market Value Exceed $262 Billion by 2019 Says a New Report Available at MarketOptimizer.org 3Health News:World Biosimilars Market Value Exceed $262 Billion by 2019 Says a New Report Available at MarketOptimizer.org 4Health News:One Brilliant Economic Survival Tool You Can Steal from the World's Best Hospitals 2Health News:One Brilliant Economic Survival Tool You Can Steal from the World's Best Hospitals 3Health News:Stem cell advance may increase efficiency of tissue regeneration 2Health News:Stem cell advance may increase efficiency of tissue regeneration 3Health News:CMSA Supports National Case Management Week Resolution Introduced in US Senate 2
... research at Rhode Island Hospital has identified a treatment in ... diagnosed, offer a poor prognosis and relatively short life expectancy. ... chemotherapy, researchers were able to inhibit tumor growth and achieve ... are published in the Journal of Oncology . ...
... ,greater than, problems, study suggests , TUESDAY, Jan. 19 ... math? , A German team of neurobiologists has found ... using specific brain cells dedicated to the comprehension of ... insight into the neurology behind human ability to comprehend ...
... , , BRAINTREE, Mass. , Jan. 19 ... leading organization of some of the country,s top physicians committed to ... Scoring System as an easy and effective way to help consumers ... ) , NuVal gives all foods a score from 1 to ...
... , NEW YORK , Jan. 19 ... the operating efficiencies and service advantages of technology while reducing ... America (Guardian) , a leading provider of employee benefits for ... its self-service benefits website, Guardian Anytime. , Guardian,s campaign will ...
... Berk Prepares to Return as CEO , ROCHESTER, N.Y. , ... today announced that on March 1 , Bradford C. ... Center while Mark B. Taubman , M.D., will begin serving ... and Dentistry .   , "I am excited to return as CEO, and ...
... 19, 2010Even after regaining normal walking speed, traumatic brain ... locomotor functions, according to a study supervised by Universit ... of Physical Medicine and Rehabilitation . Professor McFadyen,s ... a moderate or severe TBI to 7 subjects of ...
Cached Medicine News:Health News:Researchers find a treatment for deadly brain tumor 2Health News:Monkey Brain 'Hardwired' for Simple Math 2Health News:Monkey Brain 'Hardwired' for Simple Math 3Health News:Prominent Physician Organization Endorses NuVal(TM) Nutritional Scoring System 2Health News:Prominent Physician Organization Endorses NuVal(TM) Nutritional Scoring System 3Health News:Prominent Physician Organization Endorses NuVal(TM) Nutritional Scoring System 4Health News:Guardian Launches Campaign to Bolster Use of Web Capabilities to Advance Green Initiatives and Enhance Service 2Health News:Guardian Launches Campaign to Bolster Use of Web Capabilities to Advance Green Initiatives and Enhance Service 3Health News:Guardian Launches Campaign to Bolster Use of Web Capabilities to Advance Green Initiatives and Enhance Service 4Health News:New Dean of School of Medicine and Dentistry Announced 2Health News:New Dean of School of Medicine and Dentistry Announced 3Health News:Traumatic brain injuries: Motor deficits can persist even after what appears to be a full recovery 2
(Date:7/29/2014)... Cynosure, Inc. (Nasdaq: CYNO ), which ... for high-volume applications, today reported financial results for the ... results incorporate the acquisition of Palomar Medical Technologies, which ... Second-Quarter 2014 Financial Highlights , ... Non-GAAP net income of $7.1 million, or $0.32 per ...
(Date:7/29/2014)... --   What:   AFFiRiS AG, ... from a Phase I clinical trial of PD01A, a ... disease progression. The Michael J. Fox Foundation supported the ... the impact of the results for patients and the ... 2014         11.00 am ...
(Date:7/29/2014)... VIEW, Calif. , July 29, 2014 /PRNewswire/ ... has amplified with rising incidence rates and the ... of a preventative vaccine. Change is underway as ... interferon regimens towards highly effective, easily-tolerated, interferon-free oral ... Gilead,s mega blockbuster Sovaldi ...
Breaking Medicine Technology:Cynosure Reports Second-Quarter 2014 Financial Results 2Cynosure Reports Second-Quarter 2014 Financial Results 3Cynosure Reports Second-Quarter 2014 Financial Results 4Cynosure Reports Second-Quarter 2014 Financial Results 5Cynosure Reports Second-Quarter 2014 Financial Results 6Cynosure Reports Second-Quarter 2014 Financial Results 7Cynosure Reports Second-Quarter 2014 Financial Results 8Cynosure Reports Second-Quarter 2014 Financial Results 9Cynosure Reports Second-Quarter 2014 Financial Results 10Cynosure Reports Second-Quarter 2014 Financial Results 11Cynosure Reports Second-Quarter 2014 Financial Results 12Reminder/Media Advisory/AFFiRiS AG Presents Early Clinical Data on a First-of-its-Kind Parkinson's Disease Vaccine 2A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 2A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 3A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 4
... fully automated clinical chemistry analyser. It leads ... many features only seen previously on larger, ... on board reagent refrigeration and barcoding of ... can accommodate up to 40 reagent bottles, ...
Inquire...
... Lead System (Model 3830) is the worlds ... design allows for flexibility and a smaller ... thickness. The SelectSecure lead system utilizes a ... lead in select locations in either the ...
... Renin, a protease secreted by ... in the renin-angiotensin system. The renin-angiotensin ... water and electrolyte retention by the ... to several factors including decreased intravascular ...
Medicine Products: